Experience with use of recombinant activated factor VII.
Recombinant activated factor VII (rFVIIa) has recently been introduced for improving haemostasis in haemophiliac patients developing alloantibodies (inhibitors) to factor VIII (FVIII) or factor IX (FIX). We describe the successful management of haemorrhagia with rFVIIa in five different situations: an episode of surgical bleeding in a patient with haemophilia A and non-surgical haemorrhages in four patients with haemophilia A, acquired haemophilia, congenital severe FV defect and pseudo-acquired haemophilia, respectively. In each case, rFVIIa was effective and safe. There is no doubt that rFVIIa is useful in the therapeutic management of patients with antibodies to FVIII or FIX. However, the treatment is expensive and a cost-effectiveness analysis would be useful.
Divanon
F
F
Department of Pharmacy, Centre Hospitalier Universitaire, Avenue Côte de Nacre, Caen Cedex, France. divanon-f@chu-caen.fr
Hecquard
C
C
Borel-Derlon
A
A
D000328:Adult; D000368:Aged; D000917:Antibody Formation; D005168:Factor VII Deficiency / Q000188:drug therapy*; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006467:Hemophilia A / Q000150:complications* / Q000276:immunology; D006801:Humans; D007518:Isoantibodies; D008297:Male; D008875:Middle Aged
D007518:Isoantibodies; D015942:Factor VIIa